NCT02081079View on ClinicalTrials.gov

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

February 28, 2015

Conditions
Chronic Genotype 4 HCVChronic Genotype 5 HCV
Interventions
DRUG

LDV/SOF

LDV/SOF (90/400 mg) FDC tablet administered orally once daily

Trial Locations (5)

31059

Toulouse

63003

Clermont-Ferrand

87042

Limoges

92110

Clichy

94800

Villejuif

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY